Company Overview
Company Type: Private Company
Website: kardium.com
Number of Employees: 50
Year Founded: 2007
Total Amount Raised (CAD mm)†: 99.96
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Kardium Inc. operates as a medical solutions company that develops an advanced system for the treatment of atrial fibrillation (AF). It offers the Globe Mapping and Ablation System, a solution for heart rhythm disorder, atrial fibrillation (AF), offering single-shot pulmonary vein isolation, high-definition mapping, and atrial ablation in a single catheter. Also, the company engages in clinical studies of the globe system that uses pulsed-field ablation (PFA), a new energy source for cardiac ablation. Kardium Inc. was founded in 2007 and is based in Burnaby, Canada with an additional office in Dortmund, Germany.


Financial Information (Currency: CAD, in mm)
Total Revenue
 12.4
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 50
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Michelson, Amos 
Co-Founder & Chairman
Chaplin, Kevin 
CEO & Director
Goertzen, Doug 
President & COO
Gelbart, Dan 
Co-Founder & Advisor
Lichtenstein, Sam 
Co-Founder & Advisor

Key Board Members
Name
Title
Michelson, Amos 
Co-Founder & Chairman
Chaplin, Kevin 
CEO & Director
Lichtenstein, Sam 
Co-Founder & Advisor
Alba-Marquez, Manuel 
Director
Ihnatowycz, Ian Orest
Director
Rosa, David J.
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
155 – 8518 Glenlyon Parkway | Burnaby, BC | V5J 0B6 | Canada
Phone: 604 248 8891   Fax: 604 304 3478

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Fidelity Management & Research Company LLC
Dec-30-2020
Minority
-
Growth
T. Rowe Price Associates, Inc.
Feb-07-2019
Unknown
-
Growth
Big Basin Partners LP
-
Unknown
-
-
Conconi Growth Partners
-
Unknown
-
-
Marin Investments Limited
-
Unknown
-
-


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-30-2020
Jan-25-2021
Private Placement
Target
Kardium Inc.
T. Rowe Price Associates, Inc.,Fidelity Management & Research Company LLC

77.20
Feb-07-2019
Feb-07-2019
Private Placement
Target
Kardium Inc.
T. Rowe Price Associates, Inc.

-
Mar-26-2014
-
Private Placement
Target
Kardium Inc.


0.28
Jul-22-2010
-
Private Placement
Target
Kardium Inc.


0.87
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-31-2023
Product-Related Announcements
Kardium Inc. Announces First US Procedures in Pulsar Study of Globe® Pulsed Field System
Mar-15-2023
Product-Related Announcements
Kardium Announces First Patients Treated in PULSAR IDE Study of Globe® Pulsed Field System
Nov-08-2022
Product-Related Announcements
Kardium Inc. Announces Successful First-In-Human Clinical Study of Next Generation Globe Pulsed Field System
May-02-2022
Company Conference Presentations
Kardium Inc. Presents at Bloom Burton & Co. Healthcare Investor Conference, May-02-2022 11:30 AM
Apr-12-2022
Product-Related Announcements
Kardium’S Globe System Begins Clinical Trial At St. Paul's Hospital


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 02:36 AM
Kardium Inc.
Kardium Inc
Reports
48
GlobalData

Sep 15, 2023 08:14 AM
Kardium Inc.
Kardium Inc - Medical Devices Product Pipeline Summary
Reports
24
GlobalData

Aug 18, 2023 03:40 AM
Kardium Inc.
Kardium Inc - Medical Equipment - Deals and Alliances Profile
Reports
20
GlobalData

Jun 16, 2023 12:59 AM
Kardium Inc.
Kardium Inc
Reports
49
GlobalData

Jun 14, 2023 06:42 AM
Kardium Inc.
Kardium Inc - Medical Equipment - Deals and Alliances Profile
Reports
20
GlobalData

Jun 09, 2023 07:10 AM
Kardium Inc.
Kardium Inc - Medical Devices Product Pipeline Summary
Reports
25
GlobalData

Mar 17, 2023 05:44 AM
Kardium Inc.
Kardium Inc - Medical Equipment - Deals and Alliances Profile
Reports
20
GlobalData

Mar 16, 2023 02:14 AM
Kardium Inc.
Kardium Inc
Reports
47
GlobalData

Mar 11, 2023 01:34 AM
Kardium Inc.
Kardium Inc - Medical Devices Product Pipeline Summary
Reports
25
GlobalData

Dec 16, 2022 01:05 AM
Kardium Inc.
Kardium Inc
Reports
47


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Michelson, Amos 
Co-Founder & Chairman
604 248 8891
604 304 3478

Chaplin, Kevin 
CEO & Director
+1-604-248-8891
604 304 3478
kevin.chaplin@kardium.com
Lichtenstein, Sam 
Co-Founder & Advisor
604 248 8891
604 304 3478

Alba-Marquez, Manuel 
Director
604 248 8891
604 304 3478

Ihnatowycz, Ian Orest
Director
604 248 8891
604 304 3478

Rosa, David J.
Director
604 248 8891
604 304 3478

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Michelson, Amos 
Co-Founder & Chairman
604 248 8891
604 304 3478

Chaplin, Kevin 
CEO & Director
+1-604-248-8891
604 304 3478
kevin.chaplin@kardium.com
Goertzen, Doug 
President & COO
604 248 8891
604 304 3478

Gelbart, Dan 
Co-Founder & Advisor
604 248 8891
604 304 3478

Lichtenstein, Sam 
Co-Founder & Advisor
604 248 8891
604 304 3478

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
